Astral Codex Ten

U.S.

11 min read

U.S.

Article

U.S. is a recurring place in the Astral Codex Ten archive, appearing 9 times across 9 issues between January 27, 2022 and December 29, 2025. The archive places it in contexts such as “A really easy way to lower costs in the U.S. would be to require all insurance companies”; “The U.S. and Canada reach an agreement on softwood lumber”; “he can benefit from our best-in-class treatment”. It most often appears alongside China, Congress, France.

Metadata

  • Category: Places
  • Mention count: 9
  • Issue count: 9
  • First seen: January 27, 2022
  • Last seen: December 29, 2025

Appears In

Source Context

Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.

Highlights From The Comments On Health Care Systems
January 27, 2022 · Original source
United States (GDP $21T): 2007: $131B 2012: $119B 2013:$143B, 2014: $154B, 2015: $163B, 2016: $173B,2017: $182B, 2018: $194B
So we have a drug industry that basically works by researching drugs to sell them in the United States; but then also pushing the drugs through the relatively easier regulatory regimes in the rest of the world to also sell the drugs everywhere else possible where the only investment that those additional sells need to justify recouping is the cost of getting the approvals since all of the research is already done.
And we end up with a system where drug development is worthwhile if and only if those drugs end up being sold in the United States, and where the FDA has the most stringent approval process, and nobody really has an incentive to change this. American regulators and politicians get disproportionately more power out of this arrangement. Drug companies make their profits. American insurers are able to pass along and distribute the costs across the population so they make their profits too. European countries get their drugs relatively inexpensively, and are existing in a legal context where that is their only real incentives since they really can't increase their ability to regulate drugs because the power that exists there is distributed throughout the EU rather than possessed by the governments of the member states. And the members of the EC probably are a bit unhappy and trying to increase their own ability to regulate things, but they're sufficiently disconnected from the powers of the member states that what they want doesn't really matter. (So Europe has somehow found a way to make the people who have the most incentive to increase the price of drug R&D there from having their voices heard.)
Predictions For 2022
February 01, 2022 · Original source
YGLESIAS PREDICTIONS 1. Democrats lose both houses of Congress (90%) HOLD 2. Democrats lose at least two Senate seats (80%) HOLD 3. Democrats lose fewer than six Senate seats (80%) HOLD 4. Nancy Pelosi announces retirement plans (70%) HOLD 5. Stephen Breyer does not retire (60%) N/A 6. Some version of Build Back Better passes (60%) HOLD 7. Joe Biden is still president (90%) HOLD 8. At least one Biden cabinet-rank official resigns (70%) HOLD 9. No military conflict between the PRC and Taiwan (a worryingly low 90%) HOLD 10. New U.S. sanctions on Russia (70%) HOLD 11. Saudi Arabia and Israel establish diplomatic relations (60%) SELL to 50% 12. Fewer U.S. Covid deaths in 2022 than in 2021 (80%) BUY to 90% 13. Emmanuel Macron re-elected (60%) HOLD 14. Traffic light coalition exploits loopholes to get around the constitutional debt brake (70%) HOLD 15. No recession in 2021 (90%) SELL to 80% 16. Liz Cheney loses primary (80%) HOLD 17. Some version of USICA passes Congress (70%) HOLD 18. Lula elected president of Brazil (60%) SELL to 50% 19. China officially abandons Covid Zero (70%) HOLD 20. Fewer U.S. Covid-19 deaths in 2022 than in 2020 (80%) BUY to 90% 21. Additional booster shots of mRNA vaccines authorized for seniors (80%) HOLD 22. November 2022 year-on-year CPI growth is below 6% (70%) BUY to 80% 23. November 2022 year-on-year CPI growth is above 4% (70%) SELL to 50% 24. The Fed ends up doing more than its currently forecast three interest rate hikes (60%) HOLD 25. Russia does not invade Ukraine (60%) HOLD 26. Viktor Orbán loses power in Hungary (60%) HOLD 27. Sinn Fein becomes the largest party in the Northern Ireland assembly (60%) HOLD 28. The U.S. and Canada reach an agreement on softwood lumber (70%) HOLD 29. Democrats go down at least one governor on net (60%) HOLD 30. The unemployment rate stays between 4 and 5% (70%) SELL to 60% if you mean 12/22, to 40% if you mean it never gets outside that range at all
Your Book Review: The Outlier
July 08, 2022 · Original source
Carter finds more success in the arena of foreign policy, where instead of dealing with mercurial politicians from his own country, he can deal with mercurial politicians from other countries. He starts by tackling the third rail of the Panama Canal. The United States built the Canal by essentially colonizing the part of Panama it runs through, and obviously, the Panamanians aren’t super cool with that. The U.S. government has been kicking the can down the road since the LBJ era by continually promising to return sovereignty over the canal to Panama eventually, and after over a decade of “eventually,” the Panamanians are getting impatient.
The politically easy move for Carter would be to drag out the negotiations until the canal becomes the next president’s problem, just as Johnson, Nixon, and Ford all did before him. But for better or for worse, Carter almost never does the politically easy thing. “It’s obvious we cheated the Panamanians out of their canal,” he says, and he negotiates a treaty in which ownership of the canal is turned over to Panama, in exchange for the U.S.’s right to militarily ensure its “neutral operation.” It’s a clever diplomatic solution—Panama gets nominal ownership while we retain all the benefits ownership provides—but the American public hates it. To the average voter, it feels like we’re just giving some random country “our” canal.
Shortly after his escape from Iran to exile in Egypt, the Shah is diagnosed with cancer, and since he’s been a consistent American ally, lots of influential people think we should let him come to the U.S. where he can benefit from our best-in-class treatment. Carter is against the idea at first (in fact, he directly predicts that granting the Shah entry to the U.S. could lead to Americans in Iran getting taken hostage), but eventually he’s worn down by his advisors and gives in. Less than two weeks after the Shah arrives, Carter’s prediction come true: the American embassy in Iran is overrun and 52 citizens are taken hostage. Ironically, even the Shah ends up worse off, as he ultimately dies not from his cancer but from a series of avoidable medical errors made by his American doctors.
Your Book Review: The Society Of The Spectacle
July 22, 2022 · Original source
The United States exemplified the diffuse form, where the government allowed corporations and private media to operate relatively unimpeded.
This is not a fantasy - this is your news feed. The U.S. is predicting a false-flag attack by Russia in the Ukraine. Russia accused the UK of a false-flag attack in Syria. The U.S. accuses China of genocide. China and Iran claimed COVID was a U.S. bio-attack.
Inline links: a false-flag attack, accused, accuses, claimed
Your Book Review: 1587, A Year Of No Significance
August 19, 2022 · Original source
Huang first went to university to study electrical engineering, but during the World War II years he became an Army officer. He saw combat, recovered from a gunshot wound to the leg, and rose to the level of Major in an elite Chinese military unit known as the New First Army, which was aligned with U.S. forces. They battled Japanese troops in south-east Asia and, later, Chinese Communists during the Chinese Civil War. Huang graduated from the American Army Staff College in 1947, but after the victory of the Chinese Communists on the mainland, and the retreat of the Chinese Nationalists to Taiwan, Huang stayed in the U.S. and took up the study of Chinese history, obtaining a doctorate degree in 1964 (when he was 46). 1587 is his best-known and most widely acclaimed book, but he enjoyed a long and successful academic career and also contributed to Joseph Needham's opus Science and Civilisation in China.
So how well did the rest of the government function, given that the ruler was not really calling the shots, most days? I think we’ll get a better answer to that question by first zooming forward a few millennia, from ancient Egypt to the U.S.A.
Universe-Hopping Through Substack
September 29, 2022 · Original source
The space battlefield is no longer science fiction or something that only exists in Star Wars films. That’s why the Trump administration created the Space Force as an independent branch of the military in 2019. As Russia and China begin to weaponize space, the U.S. needs to invest in ways to deter this advancement.
Highlights From The Comments On Semaglutide
November 30, 2022 · Original source
Fourth, this is nitpicky, but when you say "almost 10% of all US drug spending," you are dividing a 2030 spending projection by what U.S. prescription drug spending was in ~2020. The Medicare actuaries project U.S. prescription drug spending in 2030 to be closer to 600 million, not 300 million. That's still a massive projection for spending in the obesity class. If you believe the Morgan Stanley projection, spending on the obesity class as a share of national health spending will be comparable to peak spending on the Hepatitis C drugs. The financial impact of the Hepatitis C drugs was a huge story. But this would be even bigger, because the Hepatitis C drugs were a cure, such that the spending surge was short-lived. Conversely, the obesity drugs are chronic medications, and we should probably expect volume to continue to increase post-2030.
Inline links: project, comparable
Open Letter To The NIH
August 29, 2025 · Original source
We, the undersigned scientists, doctors, and public health stakeholders, commend your commitment to spend all funds allocated to the NIH, as reported in The Washington Post. At the same time, we are concerned by reports that U.S. institutions received nearly $5 billion less in NIH awards over the past year. With less than one month to the end of the fiscal year, we submit this urgent request to ensure that your commitment is upheld. If you anticipate that all appropriated funds cannot be spent in time, we request a public disclosure of the barriers preventing the achievement of this crucial responsibility.
Spending these funds is also a competitiveness imperative as China attempts to transform itself from a low-end manufacturer to a high-tech research and innovation juggernaut. In 2024, the Chinese government increased its spending on science and technology by 10%, and the nation’s total expenditure on research and development increased by 50% in nominal terms between 2020 and 2024. As China’s number of clinical trials and new drug candidates begin to outpace the U.S., America cannot afford to allow biomedical research funding to go unspent.
Open Thread 414
December 29, 2025 · Original source
Hi, I’m X a constituent in Y. I’m calling about reports that the administration is allowing U.S. firms to sell advanced AI chips, like Nvidia’s H200, to approved customers in China.
I’m very concerned this could strengthen China’s strategic AI capabilities. Access to high-end chips is what limits how fast powerful AI models can be trained. Easing these controls risks accelerating China’s progress in military and intelligence applications, eroding the U.S. and allied lead in critical technologies.
I’m asking the Senator/Representative to push for full transparency on these export licenses, strict enforcement of end-use checks, and public hearings on whether these sales truly serve U.S. interests, and to support the GAIN AI Act.